Rafferty Asset Management
ADVM

Rafferty Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Rafferty Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,995
Closed -$84K – 1140
2022
Q2 		$84K Buy
6,995
+2,507
+56% +$26.3K ﹤0.01% 1076
2022
Q1 		$59K Sell
4,488
-423
-9% -$6.19K ﹤0.01% 1201
2021
Q4 		$86K Buy
4,911
+1,591
+48% +$31.9K ﹤0.01% 1265
2021
Q3 		$72K Sell
3,320
-41,459
-93% -$1.06M ﹤0.01% 1247
2021
Q2 		$1.57M Sell
44,779
-12,922
-22% -$696K 0.01% 748
2021
Q1 		$5.69M Buy
57,701
+49,118
+572% +$5.9M 0.04% 258
2020
Q4 		$930K Sell
8,583
-7,452
-46% -$922K 0.01% 524
2020
Q3 		$1.65M Buy
16,035
+12,573
+363% +$1.88M 0.02% 473
2020
Q2 		$723K Buy
3,462
+2,199
+174% +$389K 0.01% 620
2020
Q1 		$123K Sell
1,263
-9,466
-88% -$1.1M 0.01% 551
2019
Q4 		$1.24M Sell
10,729
-26,841
-71% -$2.37M 0.02% 497
2019
Q3 		$2.05M Buy
37,570
+33,312
+782% +$3.75M 0.03% 375
2019
Q2 		$506K Buy
+4,258
New +$352K 0.01% 688

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rafferty Asset Management's ADVM Position: Q3 2022 in Review

Rafferty Asset Management sold out of Adverum Biotechnologies (ADVM) in Q3 2022, closing a stake of 6,995 shares — an estimated $84K sold.

Rafferty Asset Management first reported a position in ADVM in Q2 2019 and held it in 13 quarters. The position peaked at $5.69M in Q1 2021. 78 funds tracked by Wall St. Rank hold ADVM as of Q3 2022.

  • Rafferty Asset Management reported no remaining Adverum Biotechnologies position as of Q3 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 6,995 Adverum Biotechnologies shares in Q3 2022, an estimated $84K.
  • Rafferty Asset Management first reported a position in Adverum Biotechnologies in Q2 2019 and held it in 13 quarters.
  • Rafferty Asset Management's Adverum Biotechnologies position peaked at $5.69M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2022.

Based on Rafferty Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.